Fifteen years of external quality assessment in leukemia/lymphoma immunophenotyping in The Netherlands and Belgium: A way forward

详细信息    查看全文

• 作者：Frank W. M. B. Preijers ; Vincent H. J. van der Velden ; Tim Preijers ; Rik A. Brooimans ; Erik Marijt ; Christa Homburg ; Kees van Montfort ; Jan W. Gratama and on behalf of the Section Immunological and Molecular Cell Diagnostics of the Foundation for Quality Assessment in Medical Laboratories(SKML)
• 刊名：Cytometry Part B: Clinical Cytometry
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：90
• 期：3
• 页码：267-278
• 全文大小：212K
• ISSN：1552-4957

文摘

In 1985, external quality assurance was initiated in the Netherlands to reduce the between-laboratory variability of leukemia/lymphoma immunophenotyping and to improve diagnostic conclusions. This program consisted of regular distributions of test samples followed by biannual plenary participant meetings in which results were presented and discussed. A scoring system was developed in which the quality of results was rated by systematically reviewing the pre-analytical, analytical, and post-analytical assay stages using three scores, i.e., correct (A), minor fault (B), and major fault (C). Here, we report on 90 consecutive samples distributed to 40–61 participating laboratories between 1998 and 2012. Most samples contained >20% aberrant cells, mainly selected from mature lymphoid malignancies (B or T cell) and acute leukemias (myeloid or lymphoblastic). In 2002, minimally required monoclonal antibody (mAb) panels were introduced, whilst methodological guidelines for all three assay stages were implemented.